4.6 Article

Selective Targeting of B Cells with Agonistic Anti-CD40 Is an Efficacious Strategy for the Generation of Induced Regulatory T2-Like B Cells and for the Suppression of Lupus in MRL/lpr Mice

Journal

JOURNAL OF IMMUNOLOGY
Volume 182, Issue 6, Pages 3492-3502

Publisher

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.0803052

Keywords

-

Categories

Funding

  1. Wellcome Trust [068629]
  2. University College of London Hospital charities Clinical Research Development Committee [G140]
  3. equipment Arthritis Research Campaign [ID 17746]
  4. Oliver Bird Rheumatism Programme [RHE/001124/G]
  5. Instituto Mexicano Del Seguro Social
  6. National Institutes of Health [R01AR044077]
  7. Versus Arthritis [17707] Funding Source: researchfish

Ask authors/readers for more resources

We have previously reported that IL-10(+) regulatory B cells, known to play an important role in controlling autoimmunity and inflammatory disorders, are contained within the transitional 2 immature (T2) B cell pool (T2 Bregs). Therapeutic strategies facilitating their enrichment or enhancing their suppressive activity are highly attractive. In this study, we report that agonistic anti-CD40 specifically targets T2 B cells and enriches Bregs upon short-term in vitro culture. Although transfer of unmanipulated T2 B cells, isolated from mice with established lupus, failed to confer protection to diseased mice, transfer of in vitro anti-CD40-generated T2 B cells (T2-like-Bregs) significantly improved renal disease and survival by an IL-10-dependent mechanism. T2-like-Bregs readily accumulated in the spleen after transfer, suppressed Th1 responses, induced the differentiation of IL-10(+)CD4(+)T cells, and conveyed a regulatory effect to CD4(+)T cells. In addition, in vivo administration of agonistic anti-CD40, currently on trial for the treatment of cancer, halted and reversed established lupus. Taken together, our results suggest a novel cellular approach for the amelioration of experimental lupus. The Journal of Immunology, 2009, 182: 3492-3502.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available